Methodological problems with ecstasy and the SCL-90

Psychopharmacology

Volumn 162, Issue 2, 2002, Pages 215-217

  Cole, Jon C ^a   Sumnall, Harry R ^a   Wagstaff, Graham F ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PSYCHEDELIC AGENT;

ANXIETY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG DEPENDENCE; DRUG EFFECT; DRUG SELF ADMINISTRATION; DRUG USE; HUMAN; IMPULSIVENESS; LETTER; MENTAL DISEASE; METHODOLOGY; MULTIPLE DRUG ABUSE; NEUROTOXICITY; OBSESSION; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOBIOLOGY; PSYCHOMETRY; RATING SCALE; RELIABILITY; SELF REPORT; SEROTONINERGIC SYSTEM; SEX RATIO; SOCIAL INTERACTION; SOCIAL PHOBIA; WORLD HEALTH ORGANIZATION; ADDICTION; CHEMICALLY INDUCED DISORDER; EVALUATION; NOTE; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS;

EVALUATION STUDIES; HALLUCINOGENS; HUMAN; MENTAL DISORDERS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOSES, SUBSTANCE-INDUCED; SUBSTANCE-RELATED DISORDERS; HUMANS;

EID: 0036304555     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1108-0     Document Type: Letter

References (30)

1. Intentional overdose and death with 3,4-methylene-dioxyethamphetamine (MDEA; "eve"): Case report
2. Neuroendocrine probes as an index of central serotonergic neurotoxicity in ecstasy users: Cannabis use is an important interfering variable
3. Hormonal, psychological, and alcohol craving changes after m-chloropiperazine administration in alcoholics
4. Serotonergic function in cocaine addicts: Prolactin responses to sequential D,L-fenfluramine challenges
5. Mood and cognitive effects of ± 3,4-methylenedioxymethamphetamine (MDMA. "ecstasy"): Week-end "high" followed by mid-week low
6. Ecstasy (MDMA) in recreational users: Self-reported psychological and physiological effects
7. Ecstasy use: Cognitive deficits related to dosage rather than self-reported problematic use of the drug
8. Serotonergic function after (±)3,4-methylene-dioxymethamphetamine ("ecstasy") in humans
9. Long-lasting effects of (±)3,4-methylenedioxymethamphetamine (Ecstasy) on serotonin system function in humans
10. Neuroendocrine effects of d-fenfluramine and bromocriptine following repeated smoked cocaine in humans
11. 2 antagonist ketanserin in healthy humans
12. Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use
13. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms
14. Pathology of deaths associated with "ecstasy" and "eve" misuse
15. Psychobiological problems in heavy "ecstasy" (MDMA) polydrug users
16. Recreational ecstasy/MDMA and other drug users from the UK and Italy: Psychiatric symptoms and psychobiological problems
17. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users
18. A new method to monitor drugs at dance venues
19. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons
20. Serotonergic blunting to meta-chlorophenylpiperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients
21. Hair concentration and self-reported abuse history of 20 amphetamine and ecstasy users
22. Analysis of illicit ecstasy tablets: Implications for clinical management in the accident and emergency department
23. MDMA nonmedical use and intoxication
24. Recreational MDMA use in Sydney: A profile of "ecstasy" users and their experiences with the drug
25. Cognitive performance and serotonergic function in users of ecstasy
26. Amphetamine-type stimulants
27. Neuroendocrine probes of serotonergic function: A critical review